BioMarin Pharmaceutical (BMRN) reported $776.13 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.1%. EPS of $0.12 for the same period compares to $0.91 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $784.4 million, representing a surprise of -1.05%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.15.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net Product Revenues- ALDURAZYME: $54 million versus the 11-analyst average estimate of $45.06 million.
- Revenues- Net Product Revenues- KUVAN: $24 million compared to the $21.1 million average estimate based on 11 analysts. The reported number represents a change of -14.3% year over year.
- Revenues- Net Product Revenues- NAGLAZYME: $122 million versus $123.14 million estimated by 11 analysts on average. Compared to the year-ago quarter, this number represents a -7.6% change.
- Revenues- Net Product Revenues- VIMIZIM: $183 million compared to the $192.42 million average estimate based on 11 analysts. The reported number represents a change of +2.8% year over year.
- Revenues- Royalty and other revenues: $15.32 million compared to the $11.31 million average estimate based on 11 analysts. The reported number represents a change of +29% year over year.
- Revenues- Net Product Revenues- PALYNZIQ: $109 million compared to the $103.1 million average estimate based on 11 analysts. The reported number represents a change of +19.8% year over year.
- Revenues- Net Product Revenues- VOXZOGO: $218 million versus the 11-analyst average estimate of $233.96 million. The reported number represents a year-over-year change of +14.7%.
- Revenues- Net Product Revenues- ROCTAVIAN: $3 million versus $9.39 million estimated by 11 analysts on average. Compared to the year-ago quarter, this number represents a -57.1% change.
- Revenues- Net product revenues: $760.81 million versus the 11-analyst average estimate of $778.49 million. The reported number represents a year-over-year change of +3.7%.
- Revenues- Net Product Revenues- BRINEURA: $48 million compared to the $43.28 million average estimate based on 11 analysts. The reported number represents a change of +29.7% year over year.
View all Key Company Metrics for BioMarin here>>>
Shares of BioMarin have returned +1.2% over the past month versus the Zacks S&P 500 composite's +2.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
